Autopsy report · NCT06456567

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

“Sponsor business decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Vor Biopharma

Sponsor type

Industry

Conditions

Systemic Lupus Erythematosus

Interventions

Telitacicept; Placebo

Participants

0

Sites

4

Countries

United States

Trials that died the same way

• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (97% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (97% match in meaning)
• Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy
  “Sponsor Corporate Business Decision” (91% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (90% match in meaning)
• Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
  “Sponsor business considerations” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.